Table 3.
Event Rates and Odds Ratios for Recurrent Stroke and Major Bleeding in SPS3-GENES Participants Randomized to Dual Antiplatelet Therapy (Aspirin and Clopidogrel) by CYP2C19 Metabolizer Phenotype
| Event | White (n=176) | Black (n=73) | Hispanic (n=244) | Overall (n=493) | ||||
|---|---|---|---|---|---|---|---|---|
| EM/UM (n=135) | IM/PM (n=41) | EM/UM (n=51) | IM/PM (n=22) | EM/UM (n=200) | IM/PM (n=44) | EM/UM (n=386) | IM/PM (n=107) | |
| Recurrent stroke | ||||||||
| n (%) | 3 (2.2) | 4 (9.8) | 6 (11.8) | 5 (22.7) | 8 (4.0) | 0 (0.0) | 17 (4.4) | 9 (8.4) |
| OR (95% CI) | Ref | 5.19 (1.08 to 24.90) | Ref | 3.45 (0.80 to 14.90) | Ref | † | Ref | 1.81 (0.76 to 4.30) |
| Major bleeding | ||||||||
| n (%) | 6 (4.4) | 3 (7.3) | 6 (11.8) | 0 (0.0) | 7 (3.5) | 1 (2.3) | 19 (4.9) | 4 (3.7) |
| OR (95% CI) | Ref | 1.54 (0.36 to 6.61) | Ref | † | Ref | 0.67 (0.08 to 5.76) | Ref | 0.67 (0.22 to 2.03) |
*2/*17 individuals excluded from analysis (n=29). EM indicates extensive metabolizer (*1/*1); IM, intermediate metabolizer (*1/*2); OR, odds ratio adjusted for age and sex and genetically defined race in the overall analysis; PM, poor metabolizer (*2/*2); SPS3-GENES indicates Secondary Prevention of Small Subcortical Strokes-Genetic Substudy; UM, ultrarapid metabolizer (*1/*17, *17/*17).
†
No events in the IM/PM group, so the OR and 95% CI cannot be estimated.